{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:42:44Z","timestamp":1790628164030,"version":"4.1.0"},"reference-count":33,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2621,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2008.01778.x","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T10:16:35Z","timestamp":1210673795000},"page":"925-931","source":"Crossref","is-referenced-by-count":22,"title":["Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine"],"prefix":"10.1155","volume":"62","author":[{"given":"K. S.","family":"Coyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Elinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Y.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. B.","family":"Glasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Jumadilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0090-4295(03)00009-8","article-title":"Estimated economic costs of overactive bladder in the United States","volume":"61","author":"Hu","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urology.2003.10.037","article-title":"Costs of urinary incontinence and overactive bladder in the United States: a comparative study","volume":"63","author":"Hu","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1185\/030079905X59076","article-title":"Overactive bladder in women: symptom impact and treatment expectations","volume":"21","author":"MacDiarmid","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1464-410X.2003.04527.x","article-title":"The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA","volume":"92","author":"Coyne","year":"2003","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1464-410X.2003.04463.x","article-title":"The impact on health-related quality of life of stress, urge and mixed urinary incontinence","volume":"92","author":"Coyne","year":"2003","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","article-title":"Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey","volume":"57","author":"Liberman","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB10|cit10","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB12|cit12","volume-title":"Important Issues in PRO Research Continued Discussions","author":"Patient Reported Outcome Harmonization Group","year":"2002"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1524-4733.1999.02210.x","article-title":"Recommendations for evaluating the validity of quality of life claims for labeling and promotion","volume":"2","author":"Leidy","year":"1999","journal-title":"Value Health"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1191\/0962280204sm357ra","article-title":"Patient reported outcomes as endpoints in medical research","volume":"13","author":"Fairclough","year":"2004","journal-title":"Stat Methods Med Res"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1472-8206.2004.00234.x","article-title":"Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life","volume":"18","author":"Wiklund","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB16|cit16","first-page":"56","article-title":"The overactive bladder: an overview for primary care health providers","volume":"44","author":"Wein","year":"1999","journal-title":"Int J Fertil Womens Med"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1742-1241.2006.00989.x","article-title":"Overactive bladder made ridiculously simple?","volume":"60","author":"Rosenberg","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"Suppl. 2A","key":"10.1111\/j.1742-1241.2008.01778.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","article-title":"Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures","volume":"68","author":"Abrams","year":"2006","journal-title":"Urology"},{"issue":"Suppl. 2A","key":"10.1111\/j.1742-1241.2008.01778.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","article-title":"Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment","volume":"68","author":"Brubaker","year":"2006","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB20|cit20","first-page":"S608","article-title":"Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder","volume":"8","author":"Kelleher","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-004-0455-3","article-title":"Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial","volume":"22","author":"Homma","year":"2004","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0149-2918(02)85137-2","article-title":"A multicenter, prospective, open-label study of tolterodine extended-release 4\u2003mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT)","volume":"24","author":"Siami","year":"2002","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1742-1241.2006.00987.x","article-title":"Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial","volume":"60","author":"Roberts","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1742-1241.2006.00986.x","article-title":"Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial","volume":"60","author":"Elinoff","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nau.20110","article-title":"Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ)","volume":"24","author":"Matza","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB28|cit28","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB29|cit29","volume-title":"Tolterodine Extended Release (ER) for Overactive Bladder (OAB): Correlations Among Improvements in Objective Symptoms, Patient Perception of Bladder Condition (PPBC), and Health-Related Quality of Life (HRQL) [Abstract 007]","author":"Van Kerrebroeck","year":"2006"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cct.2004.09.003","article-title":"Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels","volume":"25","author":"Willke","year":"2004","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB31|cit31","unstructured":"Office of New Drugs, Office of Medical Policy Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims http:\/\/www.fda.gov\/cder\/guidance\/5460dft.htm"},{"key":"10.1111\/j.1742-1241.2008.01778.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s11136-004-0706-1","article-title":"The responsiveness of the Overactive Bladder Questionnaire (OAB-q)","volume":"14","author":"Coyne","year":"2005","journal-title":"Qual Life Res"},{"issue":"Suppl. 2A","key":"10.1111\/j.1742-1241.2008.01778.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.urology.2006.05.042","article-title":"Development and validation of patient-reported outcomes measures for overactive bladder","volume":"68","author":"Coyne","year":"2006","journal-title":"Urology"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2008.01778.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2008.01778.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:00Z","timestamp":1643349960000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2008.01778.x"}},"subtitle":["Related improvements in OAB symptoms and PROs"],"short-title":[],"issued":{"date-parts":[[2008,6,28]]},"references-count":33,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01778.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6,28]]}}}